BERLIN, July 3 (Xinhua) -- German biotech firm CureVac said on Wednesday that it is selling the rights to its mRNA influenza and COVID-19 vaccines to British pharmaceutical group GSK for up to 1.45 billion euros (1.56 billion U.S. dollars) as part of a group restructuring.
After an upfront payment of 400 million euros, GSK will take control of the development, manufacturing and global commercialization of the re
